Want to see IMA full AI Analyst Report?
IMA Stock Chart & Stats
$5.90
--
Market closed
$5.90
--
Day’s Range― - ―
52-Week Range$3.94 - $18.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)69.52K
Market Cap
$69.97M
Enterprise Value-$3.72M
Total Cash (Recent Filing)$117.21M
Total Debt (Recent Filing)$8.15M
Price to Earnings (P/E)―
Beta0.96
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,279,130
10 Day Avg. Volume58,561
30 Day Avg. Volume69,515
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.25
Price to Sales (P/S)42.01
P/FCF Ratio-0.70
Enterprise Value/Market Cap-0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.77
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$13.00Price Target Upside120.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt relative to equity and sizeable assets provide durable financial flexibility for a pre-commercial biotech. This reduces insolvency risk, supports continued clinical investment without immediate debt servicing pressure, and lengthens strategic options over the next 2–6 months.
Private $30M Warrant Financing Extends RunwayThe $30M private warrant financing materially increases near-term cash available to advance late-phase plans in atopic dermatitis and expand IMG-007 into alopecia areata. That incremental funding reduces immediate dilution need and supports progression of costly clinical milestones over months.
Board And Governance ContinuityRe-election of directors, auditor ratification, and plan approval signal stable governance and oversight. Consistent board and governance frameworks improve execution credibility, streamline capital and compensation planning, and aid coordinated development strategy during clinical advancement.
Bears Say
Pre-commercial Profile: No RevenueWith no meaningful product revenue, the company remains fully dependent on capital markets and partnerships to fund operations. Until clinical success and approval generate sales, the business lacks intrinsic cash generation and faces ongoing financing exposure over the next 2–6 months.
Sustained High Cash BurnPersistent negative operating and free cash flow at ~-$52M TTM indicates substantial near-term runway consumption. Continued burn increases likelihood of additional financings or dilution and may pressure program pacing, making capital-efficient prioritization essential for sustainability.
Dilution And Registration Penalty Risk From WarrantsThe warrant financing carries clear dilution potential and contractual registration penalties if resale registration fails. This structurally raises shareholder dilution risk and creates execution requirements (timely registration) that can constrain cash use or force additional costly actions if not met.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $3.94 and its highest was $18.00 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $69.97M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
Currently, no data Available
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Undervalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 11,279,130 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImageneBio?
Currently, no hedge funds are holding shares in IMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImageneBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (120.34% Upside)
$13.00 (120.34% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.25%
12-Months-Change
Fundamentals
Return on Equity
-35.20%
Trailing 12-Months
Asset Growth
4.47%
Trailing 12-Months
Company Description
ImageneBio
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
IMA Stock 12 Month Forecast
Average Price Target
$13.00
▲(120.34% Upside)
Technical Analysis
Ownership Overview
31.09% Insiders
3.60% Mutual Funds
39.73% Other Institutional Investors
22.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---